NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
38 hedge funds and large institutions have $3.34M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
38
Holders Change
–
Holders Change %
0%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
6
Closed
3
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
+$3K
Top Buyers
1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$311K |
2 |
GBA
Garrison Bradford & Associates
New York
|
+$296K |
3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$227K |
4 |
Renaissance Technologies
New York
|
+$148K |
5 |
VF
Virtu Financial
New York
|
+$24K |
Top Sellers
1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$383K |
2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$45K |
3 |
Goldman Sachs
New York
|
-$39K |
4 |
Millennium Management
New York
|
-$11K |
5 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$4.33K |